Ming Yao, Cheng Sijing, Long Wen, Wang Hong-Lian, Xu Chuanlan, Liu Xiaoyu, Zhang Qiong, Zhao Sha, Zou Xia, Fan Junming, Wang Li, Shen Hongchun
Department of Endocrinology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Department of Nephrology, The Central Hospital of Dazhou City, Dazhou, Sichuan 635000, China.
Evid Based Complement Alternat Med. 2021 Jun 23;2021:4602612. doi: 10.1155/2021/4602612. eCollection 2021.
Chronic kidney disease (CKD) has become a global health issue, and there is increasing evidence showing the beneficial roles of traditional Chinese medicine (TCM) in CKD treatment. Here, we studied the renoprotective role of Mahuang decoction, a famous TCM prescription, in a rat CKD model induced with the combination of doxorubicin and adenine. Our data showed that intragastric administration of Mahuang decoction inhibited the loss of bodyweight and attenuated proteinuria, serum creatinine, and blood urea nitrogen in CKD rats. Kidney histological analysis revealed decreased tubulointerstitial injury and fibrosis in CKD rats treated with Mahuang decoction accompanied with suppressed expression of TGF-1 and phosphorylated NF-B/P65 (p-P65) as indicated by immunohistochemistry. ELISA analysis demonstrated reduced serum levels of proinflammatory cytokines TNF and IL-6. Most importantly, intestinal microbiota analysis by 16s rRNA-seq showed that Mahuang decoction restored the impaired richness and diversity of intestinal microflora and recovered the disrupted microbial community through reducing the abundance of deleterious microbes and promoting the expansion of beneficial microbes in CKD rats. Collectively, our findings demonstrated that Mahuang decoction mitigated kidney functional and structural impairment in CKD rats which were associated with the restoration of dysbiosis of intestinal microbiota, implying its potential in clinical CKD treatment.
慢性肾脏病(CKD)已成为一个全球性的健康问题,越来越多的证据表明中药(TCM)在CKD治疗中具有有益作用。在此,我们研究了著名的中药方剂麻黄汤对阿霉素和腺嘌呤联合诱导的大鼠CKD模型的肾脏保护作用。我们的数据表明,胃内给予麻黄汤可抑制CKD大鼠体重减轻,并减轻蛋白尿、血清肌酐和血尿素氮水平。肾脏组织学分析显示,麻黄汤治疗的CKD大鼠肾小管间质损伤和纤维化减轻,免疫组化显示TGF-1和磷酸化NF-κB/P65(p-P65)表达受到抑制。ELISA分析表明促炎细胞因子TNF和IL-6的血清水平降低。最重要的是,通过16s rRNA测序进行的肠道微生物群分析表明,麻黄汤通过降低CKD大鼠有害微生物的丰度并促进有益微生物的扩增,恢复了受损的肠道微生物群丰富度和多样性,并恢复了被破坏的微生物群落。总体而言,我们的研究结果表明,麻黄汤减轻了CKD大鼠的肾脏功能和结构损伤,这与肠道微生物群失调的恢复有关,暗示了其在临床CKD治疗中的潜力。